Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
And Hess whom on facebook asked Rettsyndrome.org Where he can find more information about the funding granted for the Anavex Clinical trial.
Which Rettsyndrome.org replied with "more information will be released soon. Thanks for your interest."
https://www.facebook.com/RettSyndrome/
What is the thinking behind the pathogen hypothesis of Alzheimer’s?
Good read on this slow day.
http://www.news-medical.net/news/20170112/Could-pathogen-infection-really-lead-to-Alzheimere28099s.aspx
"So, in general the vast majority of the AD research field has focused and continues to focus on the pathology that occurs in the disease and not on the initiating triggers for this pathology."
"Also, clinical trials to obtain biomarkers based on infections as well as those for treatment using antivirals, antibacterials, and anti-inflammatory drugs are required to establish how treating for infection can potentially influence onset and/or progression of disease following early diagnosis."
"Is it likely that Alzheimer’s could be a treatable condition one day?
Yes, but we must identify the triggers of the disease first and focus on eradicating the triggering mechanisms, in this case infections, by using antibiotics, antivirals or other anti-infectives."
"Vaccines against amyloid and other naturally occurring entities in the body are probably not going to be useful in this disease and, to date, have failed in clinical trials."
I don't care too much about interviews as he smartly lets his trial do the talking. He gave one in the past, got burned and learned from it. Im willing to guess that once ph 2/3 for Alz and ph 2 for others start rolling, he will gladly start talking. Too much work, too little time given what? 6-8 employees. = )
I will have been in this stock 2 years come July. I'm not in a rush for the pps to be out of my reach. The slower we go, the more I can accumulate along the way. What matters is that we continue moving forward and keep presenting BP worthy data.
That is probably why Missling didn't entertain the idea of being bought out. People say it's because the drug isn't proven. IMO, if Anavex was for sale @7.05 ps, we would be snatched up real quick.
If in P2/3 safety continues to be spotless, what's the chances of a-273 being an otc bottle of pills like aspirin in the future? I mean, most prescribed drugs have side effects which is why a Dr. had to prescribe them, no?
I wouldn't call it a joke MC. BP had how many years and couldn't top the soc? Poor stubborn BP. I hope we don't get bought out.
Penn study finds evidence of AD neuropathology in post-mortem brains of LBD patients
Good Read. Here is the first paragraph
Patients who had a diagnosis of Parkinson's disease (PD) with dementia (PDD) or dementia with Lewy bodies (DLB) and had higher levels of Alzheimer's disease (AD) pathology in their donated post-mortem brains also had more severe symptoms of these Lewy body diseases (LBD) during their lives, compared to those whose brains had less AD pathology, according to research from the Perelman School of Medicine at the University of Pennsylvania. In particular, the degree of abnormal tau protein aggregations, indicative of AD, most strongly matched the clinical course of the LBD patients who showed evidence of dementia prior to their deaths, the team reports in The Lancet Neurology First Online, ahead of the January print edition.
http://www.news-medical.net/news/20170106/Penn-study-finds-evidence-of-AD-neuropathology-in-post-mortem-brainsc2a0of-LBD-patients.aspx
Good point about it being the patient decision to stop using a SOC approved drug. I thought I saw a video where Dr. Mac said the patients were given an option to stop using Donez or? Also, if ALL the patients didnt stop taking dual drugs, they can't say its a mono group yet.
It's 3 months down the road. Im just saying it'll happen when it'll happen. I'm a long and could care less WHEN the PR is, as long as we continue moving positively forward.
Hoping for a PR for something 3 months down the road is kinda useless.
Now waiting for news that p2/3 has 300 patients and will start or p2 in any of the other indications will begin is something to get excited about.
P2 success is most certainly not certified. The 2a/2b isn't either. It does ,however, provide a road map to create a much more likely successful ph 2/3.
Naive is BP who refuse to try or even accept another method of attacking the disease.
Naive is those that follow. Anavex is charting their own territory. Will they fail or succeed we will know in the coming year or two.
Naive is saying that they have THE CURE. I'm not saying that, I'm just stating the obvious that some seem to conveniently step over.
Naive is those that believe Anavex is not being manipulated and pps proves what the company is worth.
Finally, what the Market wants is more % of the float out of our retail investor hands.
IMO, we are in for a wild 2017.
Good luck to you LL53
Doesn't matter how much the N value is, as long as the FDA says its ok. Whats so difficult to see that what Anavex did with N=32 BP couldn't duplicate with N=(fill in the number)
Anavex has patients laughing, playing piano, going on walks with just 32, now 25, patients.
BP had thousands of patients and did even 1, just 1, do any of that?
case closed.
What about full selling rights to A-273 with Anavex getting a percent of all sales if it gets approved along with milestone payments?
And if Biogen offered a 1:1 buyout?
Wheres Adam when you need him
Major finding: Aducanumab 10 mg/kg was associated with a near-stabilization of the MMSE score over 24 months in 15 patients in an open-label extension of a phase Ib study.
They complain about our 32 patient trial now down to 25 and Biogen reports one group taking 10mg when theres only 15 patients? Open label too
Bottom line: I guess they don't have something worth paying someone money to spread fud about.
Exactly, and in reality the FDA could possibly stop the trial at any point after once data starts showing improvement for the placebo group. Exciting times ahead.
World wide rights of A-273 ? Id rather we go alone as long as possible
How about standard of care AS placebo for ph2/3 to silence critics once and for all. After 3 months, switch to a2-73 as compassionate use and watch what our drug will do compared to soc .
Happy new year
http://m.hawaiinewsnow.com/hawaiinewsnow/pm_/contentdetail.htm?contentguid=od:QuUNUyxE
Halfway down FDA wanted analysis of result so fare em though trial wasn't done . 82 of 121 was eligible for the result readout.
Sounds like Anavex one day soon.
Too funny. Now that Anavex has something that has different results than what BP gets, now the mouse is the problem? Like it or not, they have what BP wishes they could get their hands on.
I'm thinking this extended ph2a/b will help gather the needed data to stop ph2/3 early if the endpoints are met as the drug is proven safe. I thought 2016 would of been an exciting year for Anavex, but I was wrong as the powers that be don't want this company valued too much. 2017 or 18 or 19, doesn't matter. I'm not letting go of my shares.
If it happens to drop to 3.50ish, That's when I'll be adding. Hopefully it doesn't though.
Mele Kalikimaka and bad juju to AF
When did Jan 2017 options start having 10 12.50 and 15 call and puts? Every other time it only went up to 7.50
Shorts could care less about what the company is about. Emotions are a scary thing to have when investing. I understand what you are saying though. Besides I prefer the quote from princess bride in that scenario.
"My name is Inigo Montoya. You killed my father. Prepare to die"
Like it or not, a-273 will go through a ph2/3 in at least Australia. IMO, Australia will have first approval of the drug as they understand how it helps their health system and more importantly their citizens. BP trying their best to keep this company obscure and confuse people with the fud. It's a game of chess and Missling is,so far, winning.
Dilute? Pfttt!!!!
Scam? Smart people in their respective field wouldn't dare put the respect they have on a scam.
Stupid? Lol if all else fails resort to name calling.
Thanks for your dd, but mine indicates something totally different. AF is the scum at the edge of a dirty tub. Paid by the highest payer. Good luck with your shorting and hope you learn your lesson soon.
That's a pretty good assumption being that 5 week results of the original 32 were already better than soc. So from 52-57 weeks there should have already been a noticeable difference in scores.
If he executes his plan not forgetting to cross the t's and dotting the i's, it will be peanuts compared to how much value he brought the Anavex.
Imagine how many ceos would be out of cash and desperate after being attacked again and again by jealous types.
Yep, and thankfully we are in good hands with our CEO.
Announcing we are good for at least 2 years should put a little worry on the same ones that are trying to bury us, hoping that we run out of money and have to close up shop. Hoping that we dilute so they can continue with their I told you so's. If only the Warren Buffett's of the world knew about us we would be were we truly belong. Its ok though because some of us retails know that this type of stock potential comes along once every decade or so.
Same could be said about Axovant. Employees may be a little higher.
They got the patent rights for their molecule from one glaxosmithkline who deemed it "sold to the only bidder", and by the way, before you purchase it, please know that it failed a ph3 already.
The only people that will be rich is the hedge funds that are in this gimmick. Fleecing the investors along the way.
IF one has the patience to hold. Seems like a few of us expect multi dollar days after data release. Slowly but surely we will get there, till then, don't let them take your shares on the cheap.
You were correct again. $5 expiring worthless. ????
Nope, I believe in Anavex approach vs what everyone else is still trying. Perfect example for the meaning of insanity.
The same reasons why Anavex did with 25 patients what BP could never do with 1,2, or even 3 thousand patients. You really think it's a coincidence why we are down here in the low 4's with all the great data that was released over the year? We are being held down by big $$.
They probably would convince themselves that it's a paid actor. BP hear them footsteps of little Annie getting louder.
Can you post a screenshot of the email to confirm what you quoted.
Are we not allowed to get an outstanding stock anymore like how JGB used to get for us?
And according to the shorts, it is no better than placebo. Desperate times calls for desperate measures. IMO, they can't do this for much longer before they get trapped and squeezed. Can't wait for THAT birthday present.